the development of novel neuropathic pain treatments based on GPCRs allosteric modulation theory is gaining momentum. Extensive research has shown that allosteric modulators targeting GPCRs on the ...

Septerna stood out from the crowd of biotech IPOs last year due to the lack of clinical data to hand. Now, the data are ...

Many G-protein-coupled receptors (GPCRs) possess two ligand binding sites: an orthosteric site to which endogenous ligands bind, and an allosteric site to which modulators can bind to alter the ...

Now under new ownership, the biotech has acquired the U.S. subsidiary of Korea’s GPCR Therapeutics along with a clinical-stage blood cancer drug. The deal will see Exicure take control of the ...

Septerna discontinues phase 1 clinical trial of SEP-786; plans to advance next-generation oral small molecule PTH1R agonist: South San Francisco, California Friday, February 21, 2 ...

GPCRs are a fertile source of drug targets ... Septerna is also developing SEP-631, billed as an MRGPRX2 negative allosteric modulator for the treatment of chronic spontaneous urticaria (CSU ...

Trial decision follows unanticipated events of elevated unconjugated bilirubin levelsCompany advancing multiple next-generation PTH1R agonists ...